Kevins Feeley, serving as the Chief Financial Officer for GeneDx Holdings Corp. (NASDAQ: WGS), executed a series of transactions on June 16, 2026, resulting in the disposition of 3,729 shares of the company's Class A Common Stock. The aggregate value of these sales reached approximately $226,596, with individual share prices fluctuating between $59.26 and $61.69. According to regulatory filings, these transactions were classified as "sell to cover" events. This designation indicates that the shares were liquidated specifically to satisfy tax withholding obligations associated with the vesting and settlement of restricted stock units. The reporting structure clarifies that these were not discretionary sales initiated by Mr. Feeley but rather mandatory administrative actions tied to equity compensation.
The financial mechanics of the sale were segmented into three distinct blocks. Mr. Feeley disposed of 760 shares at a weighted average price of $59.7543, with transaction prices ranging from $59.26 to $60.24 per share. A subsequent block involving 2,106 shares was sold at a weighted average price of $60.8291, with prices occurring between $60.40 and $61.35 per share. The final tranche consisted of 863 shares sold at a weighted average price of $61.5035, with prices ranging from $61.44 to $61.69 per share. Prior to these sales, Mr. Feeley acquired 7,197 shares of Class A Common Stock on the same date through the settlement of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement for no consideration. These units vest quarterly, with the first tranche having vested on June 16, 2023.
Following the reported transactions, Mr. Feeley's direct holding of GeneDx Class A Common Stock stands at 39,954 shares. He retains contingent rights to receive up to an aggregate of 82,043 shares through unvested restricted stock units and holds options to purchase up to an aggregate of 25,906 shares of Class A Common Stock, which vest according to their respective terms. The stock traded at $59.01 following these events, marking a decline of 58.6% over the past six months from a 52-week high of $170.87. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, placing it among companies on the Most Overvalued list. InvestingPro Tips highlight that the stock has taken a significant hit over the last six months and that price movements are quite volatile, noting two of ten total tips available to subscribers regarding these conditions.
Recent corporate developments at GeneDx provide context for the current market environment. The company reported its first-quarter 2026 financial results, which did not meet expectations. The company announced an earnings per share of -$0.28, missing the forecasted -$0.01. Revenue also fell short, totaling $102.3 million compared to the anticipated $112.45 million. Following this, Canaccord lowered its price target for GeneDx from $100 to $75, citing a softer revenue outlook and muted test volume expansion. Similarly, BTIG reduced its price target to $90 from $170, maintaining a Buy rating, and pointed to the company's revised 2026 revenue and volume guidance as a factor. The adjustments reflect the company's shift towards a higher mix of genome tests, which currently face slower reimbursement processes compared to exome tests. Additionally, GeneDx appointed Mark Gardner as president to focus on strengthening execution and scaling operations. These developments highlight the company's strategic adjustments amid financial challenges.